National Health (Weighted average disclosed price – first transitional disclosure cycle) Determination 2011 (No. PB 81 of 2011) (Australia)

National Health (Weighted average disclosed price – first transitional disclosure cycle) Determination 2011 (No. PB 81 of 2011)

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Unlimited Searches
Weekly Updates on New Laws
Access to 5,345,848 Global Laws from 110 Countries
View the Original Law Side-by-Side with the Translation

Subscribe Now for only USD$40 per month.

National Health (Weighted average disclosed price – first transitional disclosure cycle) Determination 2011
Instrument number PB 81 of 2011
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary (Acting), Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this determination under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the National Health Act 1953.
Dated 13 December 2011

FELICITY McNEILL

First Assistant Secretary (Acting)
Pharmaceutical Benefits Division
Department of Health and Ageing

Part 1         Preliminary
1              Name of Determination
       (1)     This Determination is the National Health (Weighted average disclosed price – first transitional disclosure cycle) Determination 2011.
       (2)     This Determination may also be cited as PB 81 of 2011.
2              Commencement
                This Determination commences on the day after it is registered.
3                   Revocation

The Determination titled ‘Determination made pursuant to subsections 99ADB(4) and 99ADB(5) of the National Health Act 1953’ made on 22 September 2010 and also cited as PB 43 of 2010 is revoked.
4                   Definitions

In this Determination:

Act means the National Health Act 1953.

adjusted approved ex-manufacturer price has the same meaning as in subsection 99ADB(1) of the Act.

adjusted approved price to pharmacists has the same meaning as in subsection 99ADB(1) of the Act.

first transitional disclosure cycle has the same meaning as in Part 2 Transitional, regulation 4, of the National Health (Pharmaceutical Benefits) Amendment Regulations 2010 (No.5) (296/2010).

unadjusted price reduction has the same meaning as in subsection 99ADB(1) of the Act.

weighted average disclosed price has the same meaning as in subsection 99ADB(1) of the Act.

5                   Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is at least 10%

For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 1 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 1.

6                   Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is less than 10%

For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 2 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 2.

7                   Adjusted approved ex-manufacturer price for brands of pharmaceutical items – unadjusted price reduction is at least 10%

For paragraph 99ADB(4) of the Act, the adjusted approved ex-manufacturer price for a brand of pharmaceutical item specified in column 2 of Schedule 1 is an amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 5 of this instrument.

8                   Adjusted approved price to pharmacists for brands of pharmaceutical items – unadjusted price reduction is at least 10%

For paragraph 99ADB(4) of the Act, the adjusted approved price to pharmacists specified in column 4 of an item in Schedule 1 is the adjusted approved price to pharmacists for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 1.

9                   Reduction Day

For paragraph 99ADH(1)(aa) of the Act, a brand of pharmaceutical item in the first transitional disclosure cycle with a data collection period ending at the end of
30 September 2011 has a reduction day of 1 April 2012.
Schedule 1

Brands of pharmaceutical items – unadjusted price reduction is at least 10%

Column 1
Column 2
Column 3
Column 4

Item
Brand of Pharmaceutical Item
Weighted average disclosed price
Adjusted approved price to pharmacists

Listed Drug
Form
Manner of administration
Brand

1
Alendronic Acid
Tablet 40 mg (as alendronate sodium)
Oral
Fosamax 40 mg
56.35
60.59

2
Alendronic Acid
Tablet 70 mg (as alendronate sodium)
Oral
Adronat
17.07
18.35

3
Alendronic Acid
Tablet 70 mg (as alendronate sodium)
Oral
Alendro Once Weekly
17.07
18.35

4
Alendronic Acid
Tablet 70 mg (as alendronate sodium)
Oral
Alendrobell 70mg
17.07
18.35

5
Alendronic Acid
Tablet 70 mg (as alendronate sodium)
Oral
Alendronate Sandoz
17.07
18.35

6
Alendronic Acid
Tablet 70 mg (as alendronate sodium)
Oral
Alendronate-GA
17.07
18.35

7
Alendronic Acid
Tablet 70 mg (as alendronate sodium)
Oral
APO-Alendronate
17.07
18.35

8
Alendronic Acid
Tablet 70 mg (as alendronate sodium)
Oral
Chem mart Alendronate 70mg
17.07
18.35

9
Alendronic Acid
Tablet 70 mg (as alendronate sodium)
Oral
Fosamax Once Weekly
17.07
18.35

10
Alendronic Acid
Tablet 70 mg (as alendronate sodium)
Oral
Ossmax 70mg
17.07
18.35

11
Alendronic Acid
Tablet 70 mg (as alendronate sodium)
Oral
Terry White Chemists Alendronate 70mg
17.07
18.35

12
Cisplatin
I.V. injection 10 mg in 10 mL
Injection
Pfizer Australia Pty Ltd
2.78
2.99

13
Cisplatin
I.V. injection 100 mg in 100 mL
Injection
Cisplatin Ebewe
18.79
20.20

14
Cisplatin
I.V. injection 100 mg in 100 mL
Injection
Hospira Pty Limited
18.79
20.20

15
Cisplatin
I.V. injection 100 mg in 100 mL
Injection
Pfizer Australia Pty Ltd
18.79
20.20

16
Cisplatin
I.V. injection 50 mg in 50 mL
Injection
Hospira Pty Limited
7.46
8.02

17
Cisplatin
I.V. injection 50 mg in 50 mL
Injection
Pfizer Australia Pty Ltd
7.46
8.02

18
Fluconazole
Capsule 100 mg
Oral
DBL Fluconazole
55.24
59.39

19
Fluconazole
Capsule 100 mg
Oral
Diflucan
55.24
59.39

20
Fluconazole
Capsule 100 mg
Oral
Dizole 100
55.24
59.39

21
Fluconazole
Capsule 100 mg
Oral
Fluconazole Sandoz
55.24
59.39

22
Fluconazole
Capsule 100 mg
Oral
Ozole
55.24
59.39

23
Fluconazole
Capsule 200 mg
Oral
APO-Fluconazole
107.61
115.70

24
Fluconazole
Capsule 200 mg
Oral
DBL Fluconazole
107.61
115.70

25
Fluconazole
Capsule 200 mg
Oral
Diflucan
107.61
115.70

26
Fluconazole
Capsule 200 mg
Oral
Dizole 200
107.61
115.70

27
Fluconazole
Capsule 200 mg
Oral
Fluconazole Sandoz
107.61
115.70

28
Fluconazole
Capsule 200 mg
Oral
Fluzole 200
107.61
115.70

29
Fluconazole
Capsule 200 mg
Oral
Ozole
107.61
115.70

30
Fluconazole
Capsule 50 mg
Oral
DBL Fluconazole
28.36
30.49

31
Fluconazole
Capsule 50 mg
Oral
Diflucan
28.36
30.49

32
Fluconazole
Capsule 50 mg
Oral
Dizole 50
28.36
30.49

33
Fluconazole
Capsule 50 mg
Oral
Fluconazole Sandoz
28.36
30.49

34
Fluconazole
Capsule 50 mg
Oral
Fluzole 50
28.36
30.49

35
Fluconazole
Capsule 50 mg
Oral
Ozole
28.36
30.49

36
Topiramate
Capsule 15 mg
Oral
Topamax Sprinkle
17.68
19.01

37
Topiramate
Capsule 25 mg
Oral
Topamax Sprinkle
23.90
25.70

38
Topiramate
Capsule 50 mg
Oral
Topamax Sprinkle
39.84
42.84

39
Topiramate
Tablet 100 mg
Oral
APO-Topiramate
62.75
67.47

40
Topiramate
Tablet 100 mg
Oral
Epiramax 100
62.75
67.47

41
Topiramate
Tablet 100 mg
Oral
RBX Topiramate
62.75
67.47

42
Topiramate
Tablet 100 mg
Oral
Tamate
62.75
67.47

43
Topiramate
Tablet 100 mg
Oral
Topamax
62.75
67.47

44
Topiramate
Tablet 100 mg
Oral
Topiramate generichealth
62.75
67.47

45
Topiramate
Tablet 100 mg
Oral
Topiramate Sandoz
62.75
67.47

46
Topiramate
Tablet 100 mg
Oral
Topiramate-GA
62.75
67.47

47
Topiramate
Tablet 200 mg
Oral
APO-Topiramate
105.41
113.34

48
Topiramate
Tablet 200 mg
Oral
Epiramax 200
105.41
113.34

49
Topiramate
Tablet 200 mg
Oral
RBX Topiramate
105.41
113.34

50
Topiramate
Tablet 200 mg
Oral
Tamate
105.41
113.34

51
Topiramate
Tablet 200 mg
Oral
Topamax
105.41
113.34

52
Topiramate
Tablet 200 mg
Oral
Topiramate generichealth
105.41
113.34

53
Topiramate
Tablet 200 mg
Oral
Topiramate Sandoz
105.41
113.34

54
Topiramate
Tablet 200 mg
Oral
Topiramate-GA
105.41
113.34

55
Topiramate
Tablet 25 mg
Oral
APO-Topiramate
24.30
26.13

56
Topiramate
Tablet 25 mg
Oral
Epiramax 25
24.30
26.13

57
Topiramate
Tablet 25 mg
Oral
RBX Topiramate
24.30
26.13

58
Topiramate
Tablet 25 mg
Oral
Tamate
24.30
26.13

59
Topiramate
Tablet 25 mg
Oral
Topamax
24.30
26.13

60
Topiramate
Tablet 25 mg
Oral
Topiramate generichealth
24.30
26.13

61
Topiramate
Tablet 25 mg
Oral
Topiramate Sandoz
24.30
26.13

62
Topiramate
Tablet 25 mg
Oral
Topiramate-GA
24.30
26.13

63
Topiramate
Tablet 50 mg
Oral
APO-Topiramate
39.89
42.89

64
Topiramate
Tablet 50 mg
Oral
Epiramax 50
39.89
42.89

65
Topiramate
Tablet 50 mg
Oral
RBX Topiramate
39.89
42.89

66
Topiramate
Tablet 50 mg
Oral
Tamate
39.89
42.89

67
Topiramate
Tablet 50 mg
Oral
Topamax
39.89
42.89

68
Topiramate
Tablet 50 mg
Oral
Topiramate generichealth
39.89
42.89

69
Topiramate
Tablet 50 mg
Oral
Topiramate Sandoz
39.89
42.89

70
Topiramate
Tablet 50 mg
Oral
Topiramate-GA
39.89
42.89

Schedule 2

Brands of pharmaceutical items – unadjusted price reduction is less than 10%

Column 1
Column 2
Column 3

Item
Brand of Pharmaceutical Item
Weighted average disclosed price

Listed Drug
Form
Manner of administration
Brand

1
Levodopa with Carbidopa
Tablet 100 mg-25 mg (anhydrous)
Oral
Kinson
25.47

2
Levodopa with Carbidopa
Tablet 100 mg-25 mg (anhydrous)
Oral
Sinemet 100/25
25.47

3
Levodopa with Carbidopa
Tablet 250 mg-25 mg (anhydrous)
Oral
Levo/Carbidopa Sandoz
31.41

4
Levodopa with Carbidopa
Tablet 250 mg-25 mg (anhydrous)
Oral
Sinemet
31.41

5
Naltrexone
Tablet containing naltrexone hydrochloride 50 mg
Oral
Naltrexone generichealth
108.89

6
Naltrexone
Tablet containing naltrexone hydrochloride 50 mg
Oral
ReVia
108.89

Note
1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.frli.gov.au.